In addition, some studies have found that glycogen synthesizer kinase 3 (GSK-3) beta inhibitor TWS119 may suppress rtPA-induced HT and decrease BBB damage by activating Wnt/β-catenin signaling pathway in rats with acute ischemic stroke (Wang et al., 2016, 2017). The gene discussed is GSK3B; the disease is hematocrit.